Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of injectable dexlansoprazole for upper gastrointestinal bleeding caused by gastric and/or duodenal ulcer
CTR20250500Phase 3Completed
- Sponsor
- Nanjing Haina Pharmaceutical Technology
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dexlansoprazole in Peptic ulcer disease (PUD), upper gastrointestinal bleeding (UGIB), sponsored by Nanjing Haina Pharmaceutical Technology. Started Mar 2025; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
Peptic ulcer disease (PUD)upper gastrointestinal bleeding (UGIB)
Beyond the preview
Go deeper on CTR20250500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250500.